Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Gilead Sciences (NASDAQ:GILD) had its price target raised by research analysts at JPMorgan Chase & Co. from $100.00 to $105.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price target points to a potential upside of 8.04% from the company’s previous close.

A number of other analysts have also recently weighed in on GILD. BMO Capital Markets boosted their price objective on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research note on Thursday. Wells Fargo & Company upped their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday. Robert W. Baird increased their price target on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research report on Thursday. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Thursday. Finally, Evercore ISI raised Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Eleven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $90.05.

Gilead Sciences Trading Up 6.0 %

Shares of Gilead Sciences stock traded up $5.50 during trading on Thursday, hitting $97.19. The stock had a trading volume of 8,544,501 shares, compared to its average volume of 7,018,311. The stock has a 50 day simple moving average of $84.58 and a 200 day simple moving average of $74.67. The company has a market capitalization of $121.00 billion, a PE ratio of 118.59, a P/E/G ratio of 3.13 and a beta of 0.17. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. Gilead Sciences has a 1 year low of $62.07 and a 1 year high of $98.32.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The firm had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same period in the previous year, the company earned $2.29 earnings per share. The company’s revenue was up 7.0% compared to the same quarter last year. On average, research analysts expect that Gilead Sciences will post 3.75 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 5,490 shares of the stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the transaction, the insider now directly owns 114,979 shares in the company, valued at $8,506,146.42. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the sale, the insider now owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 5,490 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the transaction, the insider now owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 36,847 shares of company stock worth $3,033,340 in the last ninety days. Corporate insiders own 0.29% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

A number of large investors have recently bought and sold shares of GILD. nVerses Capital LLC bought a new stake in shares of Gilead Sciences during the third quarter valued at approximately $25,000. Valued Wealth Advisors LLC increased its position in Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 161 shares in the last quarter. CarsonAllaria Wealth Management Ltd. increased its position in Gilead Sciences by 198.3% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 238 shares in the last quarter. Strategic Investment Solutions Inc. IL purchased a new stake in Gilead Sciences in the second quarter worth about $33,000. Finally, Cedar Wealth Management LLC boosted its stake in shares of Gilead Sciences by 51.6% in the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 160 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.